An antimicrobial peptide WRKB7 and its preparation method and application
By developing the antimicrobial peptide WRKB7, the problem of insufficient antioxidant function in the existing antimicrobial peptides was solved, and effective inhibition and free radical removal of Staphylococcus aureus and E. coli was achieved. It has stability and low toxicity and is suitable for the treatment of skin inflammation. and antioxidant products.
Patent Information
- Application Number
- CN202211539371.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-02
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2042-12-02
AI Technical Summary
There are fewer types of existing antimicrobial peptides that have antioxidant effects, making it difficult to effectively solve the dual problems of oxidative pressure and microbial infection.
A kind of antibacterial peptide WRKB7 has been developed, with an amino acid sequence of IRVWGCIVKRL. The crude peptide was synthesized by solid phase synthesis method, and high performance liquid chromatography purification technology was used, combined with matrix-assisted laser analytical ionization time-of-flight mass spectrometry to prepare significant antibacterial and anti-flight Polypeptides with oxidation function.
WRKB7 has significant antibacterial activity against Staphylococcus aureus and E. coli, and has good free radical scavenging ability, high stability, low side effects, low hemolytic activity, and no cytotoxicity. It is suitable for skin inflammation treatment and antioxidant product.
Smart Images

Figure CN115925797B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of antimicrobial peptides, and in particular relates to an antimicrobial peptide WRKB7 and a preparation method and application thereof. Background Art
[0002] Antibacterial peptides (ABPs), also known as antimicrobial peptides, originally refer to a class of alkaline polypeptide substances with a molecular weight of about 4kD and antibacterial activity that are induced in insects. They were first discovered by Swedish scientist Boman in 1972 in Hyalophora cecropia and named cecropins. Since then, scientists have successively isolated polypeptides with broad-spectrum antibacterial and antimicrobial activities from a variety of organisms. Therefore, the concept of antimicrobial peptides has been expanded, and it refers to polypeptides with antibacterial activity that exist in organisms. It has been found that in addition to the antiviral, antibacterial and antifungal functions, some AMPs also have strong antioxidant functions and the effect of scavenging free radicals. However, there are few types of antimicrobial peptides with antioxidant effects reported so far. Summary of the invention
[0003] In view of this, the object of the present invention is to provide an antimicrobial peptide WRKB7 and a preparation method and application thereof. The antimicrobial peptide WRKB7 also has an antioxidant effect.
[0004] The present invention provides an antimicrobial peptide WRKB7, the amino acid sequence of which is shown in SEQ ID No.1.
[0005] The present invention also provides a method for preparing the antimicrobial peptide WRKB7 described in the above scheme, comprising the following steps: synthesizing a crude polypeptide using a solid phase synthesis method according to the amino acid sequence shown in SEQ ID No.1.
[0006] Preferably, after the crude polypeptide is synthesized, the crude polypeptide is further purified; the purification includes high performance liquid chromatography purification.
[0007] Preferably, the HPLC purification comprises: dissolving the crude polypeptide in a trifluoroacetic acid aqueous solution with a volume concentration of 0.1% to obtain a sample to be tested, loading the sample to be tested, performing gradient elution using a binary mobile phase, and detecting at a wavelength of 215 nm at 25° C.;
[0008] The binary mobile phase includes mobile phase A and mobile phase B; the mobile phase A is a trifluoroacetic acid aqueous solution with a volume concentration of 0.1%; the mobile phase B is a trifluoroacetic acid acetonitrile solution with a volume concentration of 0.1%;
[0009] The procedure of the gradient elution is as follows: within 30 minutes, the content of mobile phase B in the eluent increases linearly from 0% to 80%;
[0010] The eluent flow rate of the gradient elution is 1 mL / min;
[0011] The chromatographic column for high performance liquid chromatography purification is a silica gel alkyl bonded phase C18 column.
[0012] Preferably, after purifying the crude polypeptide, the method further comprises determining the molecular weight and isoelectric point of the purified polypeptide.
[0013] Preferably, the determining the molecular weight of the purified polypeptide comprises determining the molecular weight of the purified polypeptide using matrix-assisted laser desorption ionization time-of-flight mass spectrometry;
[0014] The method of using matrix-assisted laser desorption ionization time-of-flight mass spectrometry to determine the molecular weight of the purified polypeptide comprises:
[0015] dissolving the purified polypeptide in deionized water to obtain a purified polypeptide solution;
[0016] Mixing the purified polypeptide solution and the saturated matrix solution to obtain a sample to be tested;
[0017] Determine the molecular weight of the sample using matrix-assisted laser desorption ionization time-of-flight mass spectrometry;
[0018] The concentration of the purified polypeptide in the purified polypeptide solution is 1 μmol / mL;
[0019] The volume ratio of the purified polypeptide solution to the saturated matrix solution is 1:1;
[0020] The preparation method of the saturated matrix solution comprises:
[0021] Dissolving α-cyano-4-hydroxycinnamic acid in acetonitrile solution to prepare a saturated solution, centrifuging, and taking the supernatant to obtain a saturated matrix solution;
[0022] The acetonitrile solution uses an acetonitrile aqueous solution with a volume concentration of 50% as a solvent and contains trifluoroacetic acid with a volume concentration of 0.1%.
[0023] The present invention also provides the use of the antimicrobial peptide WRKB7 described in the above scheme or the antimicrobial peptide WRKB7 prepared by the preparation method in the preparation of antimicrobial and / or antioxidant products.
[0024] Preferably, the types of antibacterial bacteria include Staphylococcus aureus and / or Escherichia coli.
[0025] The present invention also provides the use of the antimicrobial peptide WRKB7 described in the above scheme or the antimicrobial peptide WRKB7 prepared by the preparation method in the preparation of medicines for treating skin inflammation.
[0026] The present invention also provides a cosmetic or medicine containing the antimicrobial peptide WRKB7 described in the above scheme or the antimicrobial peptide WRKB7 prepared by the preparation method.
[0027] The present invention also provides the use of the antimicrobial peptide WRKB7 described in the above scheme or the antimicrobial peptide WRKB7 prepared by the preparation method in the preparation of medicines for treating skin inflammation.
[0028] The present invention provides an antimicrobial peptide WRKB7, the amino acid sequence of which is shown in SEQ ID No. 1. The antimicrobial peptide WRKB7 of the present invention not only has significant antimicrobial activity, but also has an antioxidant function. The minimum inhibitory concentrations of the antimicrobial peptide WRKB7 of the present invention for the standard strain of Staphylococcus aureus (Staphylococcus aureus ATCC2592) and the standard strain of Escherichia coli (Escherichia coli ATCC25922) are 3.24 μg / ml and 6.56 μg / ml, respectively. The antimicrobial peptide WRKB7 has good free radical scavenging ability, and the scavenging rate of DPPH free radicals is 46.8±5.2%. In addition, the antimicrobial peptide WRKB7 of the present invention has good stability and low side effects. After WRKB7 was incubated with serum for 10 hours, the antimicrobial activity can still be detected. In addition, the hemolytic activity of the antimicrobial peptide WRKB7 is low, and the cytotoxicity assay is performed using the human embryonic kidney cell line HEK293T, and the antimicrobial peptide WRKB7 has high cell proliferation ability and no cytotoxicity. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0030] Figure 1 The results of the hemolytic activity assay of WRKB7;
[0031] Figure 2 The results of the cytotoxic activity assay of WRKB7 are shown;
[0032] Figure 3 These are the results of the plasma stability test of WRKB7. DETAILED DESCRIPTION
[0033] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0034] The present invention provides an antimicrobial peptide WRKB7, the amino acid sequence of which is shown in SEQ ID No. 1, specifically: IRVWGCIVKRL.
[0035] In the present invention, the molecular weight of the antimicrobial peptide WRKB7 is 1342.69 Da; the isoelectric point of the antimicrobial peptide WRKB7 is 10.86.
[0036] The present invention also provides a method for preparing the antimicrobial peptide WRKB7 described in the above scheme, comprising the following steps: synthesizing a crude polypeptide using a solid phase synthesis method according to the amino acid sequence shown in SEQ ID No.1.
[0037] In the present invention, the polypeptide is synthesized by solid phase synthesis, which has low cost and high quality controllability.
[0038] After the crude polypeptide is synthesized, the present invention preferably further comprises purifying the crude polypeptide; the purification comprises high performance liquid chromatography (HPLC) purification; the high performance liquid chromatography purification is preferably HPLC reverse phase column chromatography desalting purification.
[0039] In the present invention, the HPLC purification preferably comprises: dissolving the crude polypeptide in a trifluoroacetic acid aqueous solution with a volume concentration of 0.1% to obtain a sample to be tested, loading the sample to be tested, using a binary mobile phase for gradient elution, and detecting at a wavelength of 215 nm at 25° C. In the present invention, the solvent of the trifluoroacetic acid aqueous solution is preferably ultrapure water.
[0040] In the present invention, the sample to be tested is preferably loaded after the baseline is stabilized.
[0041] In the present invention, the loading volume of the sample to be tested is preferably 50 μL.
[0042] In the present invention, the binary mobile phase includes mobile phase A and mobile phase B; the mobile phase A is a trifluoroacetic acid aqueous solution with a volume concentration of preferably 0.1%; the mobile phase B is a trifluoroacetic acid acetonitrile solution with a volume concentration of preferably 0.1%.
[0043] In the present invention, the gradient elution procedure is preferably as follows: within 30 minutes, the content of mobile phase B in the eluent increases linearly from 0% to 80%.
[0044] In the present invention, the eluent flow rate of the gradient elution is preferably 1 mL / min.
[0045] In the present invention, the chromatographic column for HPLC purification is preferably a silica gel alkyl bonded phase C18 column.
[0046] After purifying the crude polypeptide, the present invention preferably further comprises identifying the purity of the purified polypeptide until the purity of the polypeptide is not less than 95%.
[0047] After purifying the crude polypeptide, the present invention preferably further comprises determining the molecular weight and isoelectric point of the purified polypeptide.
[0048] In the present invention, the determination of the molecular weight of the purified polypeptide preferably comprises determining the molecular weight of the purified polypeptide using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF), and the molecular weight of the purified polypeptide is determined to be 1342.69 Da.
[0049] In the present invention, the molecular weight of the purified polypeptide determined by matrix-assisted laser desorption ionization time-of-flight mass spectrometry preferably includes:
[0050] dissolving the purified polypeptide in deionized water to obtain a purified polypeptide solution;
[0051] Mixing the purified polypeptide solution and the saturated matrix solution to obtain a sample to be tested;
[0052] The molecular weight of the sample to be tested is determined using matrix-assisted laser desorption ionization time-of-flight mass spectrometry.
[0053] In the present invention, the solvent of the purified polypeptide solution is preferably deionized water; the concentration of the purified polypeptide in the purified polypeptide solution is preferably 1 μmol / mL.
[0054] In the present invention, the volume ratio of the purified polypeptide solution to the saturated matrix solution is preferably 1: 1. The sampling volume of the purified polypeptide solution is preferably 10 μL.
[0055] In the present invention, the method for preparing the saturated matrix solution preferably comprises:
[0056] α-Cyano-4-hydroxycinnamic acid is dissolved in acetonitrile solution to prepare a saturated solution, and the solution is centrifuged and the supernatant is collected to obtain a saturated matrix solution.
[0057] In the present invention, the acetonitrile solution preferably uses an acetonitrile aqueous solution with a volume concentration of 50% as a solvent, and contains trifluoroacetic acid with a volume concentration of 0.1%.
[0058] In the present invention, the centrifugal speed is preferably 10,000 rpm; the centrifugal time is preferably 8 to 12 min, more preferably 10 min.
[0059] In the present invention, the isoelectric point of the purified polypeptide is preferably determined by isoelectric focusing electrophoresis, and the isoelectric point of the purified polypeptide is 10.86.
[0060] After purifying the crude polypeptide, the present invention preferably further comprises determining the amino acid sequence structure of the purified polypeptide.
[0061] In the present invention, the amino acid sequence structure of the purified polypeptide is preferably determined by an automatic amino acid sequencer, and the amino acid sequence structure of the purified polypeptide is Ile-Arg-Val-Trp-Gly-Cys-Ile-Val-Lys-Arg-Leu.
[0062] The present invention also provides the use of the antimicrobial peptide WRKB7 described in the above scheme in the preparation of cosmetics.
[0063] The present invention also provides a cosmetic or medicine containing the antimicrobial peptide WRKB7 described in the above scheme or the antimicrobial peptide WRKB7 prepared by the preparation method.
[0064] In the present invention, the cosmetics preferably further include other raw materials and / or auxiliary materials; the auxiliary materials preferably include one or more of physiological saline, pure water, mannitol, polyols, glycerol, lanolin, mineral oil and vegetable oil; the raw materials are selected from one or more of other proteins, other polypeptides, plant extracts, cytokines and vitamins.
[0065] The present invention also provides the use of the antimicrobial peptide WRKB7 described in the above scheme or the antimicrobial peptide WRKB7 prepared by the preparation method in the preparation of antimicrobial and / or antioxidant products.
[0066] In the present invention, the types of antibacterial bacteria include Staphylococcus aureus and / or Escherichia coli.
[0067] In the present invention, the product preferably includes cosmetics or medicines.
[0068] In the present invention, the cosmetics preferably include skin care products; the skin care products can regulate skin microorganisms and resist oxidation.
[0069] The present invention also provides the use of the antimicrobial peptide WRKB7 described in the above scheme or the antimicrobial peptide WRKB7 prepared by the preparation method in the preparation of medicines for treating skin inflammation.
[0070] In the present invention, the dosage form of the drug is an external dosage form, preferably a liniment or a spray.
[0071] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention.
[0072] Example 1
[0073] (1) According to the designed amino acid sequence:
[0074] Ile-Arg-Val-Trp-Gly-Cys-Ile-Val-Lys-Arg-Leu, the crude peptide was synthesized by solid phase synthesis;
[0075] (2) desalting and purifying the crude polypeptide by HPLC reverse phase column chromatography, and identifying its purity until the purity of the polypeptide is not less than 95%;
[0076] HPLC purification and identification method:
[0077] 0.1 mg of the sample to be tested was dissolved in 1 mL of ultrapure water containing 0.1% trifluoroacetic acid. If there were insoluble impurities, the sample was filtered with a 0.45 μm filter membrane. Mobile phase A was 0.1% trifluoroacetic acid-water, and mobile phase B was 0.1% trifluoroacetic acid-acetonitrile. Sample loading began after the baseline was stable, and the sample loading volume was 50 μL. The chromatographic column was a silica gel alkyl bonded phase C18 column (4.6 mm×300 mm, colloid size 5 μm, pore size 100A), and a binary mobile phase gradient elution system was used for gradient elution, that is, within 30 minutes, the content of mobile phase B in the eluent increased linearly from 0% to 80%, the flow rate was 1 mL / min, the detection wavelength was 215 nm, and the measurement was performed at 25°C.
[0078] (3) Its molecular weight was determined to be 1342.69 Da by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF);
[0079] Method: The purified peptide was dissolved in deionized water to prepare a 1 μmol / mL solution. 10 μL was mixed with an equal volume of saturated matrix solution (α-cyano-4-hydroxycinnamic acid was dissolved in 50% acetonitrile solution containing 0.1% trifluoroacetic acid to prepare a saturated solution, centrifuged, and the supernatant was taken for determination.
[0080] (4) The isoelectric point of the purified polypeptide was determined to be 10.86 by isoelectric focusing electrophoresis, and the amino acid sequence structure of the purified polypeptide was determined by an automatic amino acid sequencer and was determined to be Ile-Arg-Val-Trp-Gly-Cys-Ile-Val-Lys-Arg-Leu.
[0081] Experimental Example 2
[0082] Antimicrobial activity testing
[0083] The minimum inhibitory concentration is the lowest drug concentration that can inhibit bacterial growth and reproduction. The experiment uses a two-fold gradient dilution method. The specific experimental operation is as follows: prepare fresh bacterial solution, use a UV spectrophotometer to detect the OD600 of the bacterial solution, and follow the formula 1OD600 = 1×10 9 CFU / ml, and dilute the above bacterial solution with fresh LB liquid medium to adjust the concentration to 2×10 5 CFU / ml. Then, 100 μl of physiological saline was added to a sterile 96-well plate, and the sample to be tested was added to the first well. The sample to be tested was diluted two-fold in sequence, and then 100 μl of a 2×10 5 CFU / ml of bacterial solution was pipetted and mixed, and then placed in a 37°C constant temperature incubator for overnight culture. Finally, the light absorption value of the bacterial solution at 600nm was detected by an ELISA instrument, and the average value of the sample concentration of the well where no bacterial growth was detected and the adjacent wells was taken as the minimum inhibitory concentration, i.e., the MIC value. The antibacterial activity of polypeptide WRKB7 is shown in Table 1.
[0084] Table 1 Minimum inhibitory concentration of peptide WRKB7 against standard strains
[0085]
[0086] As can be seen from Table 1, the minimum inhibitory concentrations of the polypeptide WRKB7 against the standard strain of Staphylococcus aureus (Staphylococcus aureus ATCC2592) and the standard strain of Escherichia coli (Escherichia coli ATCC25922) are 3.24 μg / ml and 6.56 μg / ml respectively.
[0087] The above experimental results indicate that the polypeptide WRKB7 provided by the present invention has a good antibacterial effect.
[0088] Experimental Example 3
[0089] Hemolytic activity and cytotoxicity assays
[0090] Use saline to dilute the washed red blood cells to a density of 10 7 -10 8 / ml, and the samples to be tested were prepared into different gradient concentrations, and the two were placed at 37°C for co-incubation for 30 minutes, followed by centrifugation at 1000rpm for 5 minutes, and the light absorption value of the supernatant at 540nm was detected by an enzyme marker. In this experiment, physiological saline was used as a negative control, and the same volume of TritonX-100 (10%) was used as a positive control. The hemolytic activity was proportional to the light absorption value at 540nm.
[0091] Hemolytic activity Figure 1 As shown, WRKB7 has low hemolytic activity.
[0092] The human embryonic kidney cell line HEK293T was used for cytotoxicity assay. When the cells grew well and the density reached 80% of the bottom of the bottle, the culture medium was discarded and washed three times with sterile PBS. The adherent cells were then digested with trypsin. After termination, fresh DMEM culture medium containing 10% FBS was added and mixed by pipetting, and the concentration of the cell suspension was adjusted to 5×10 5 / ml, the experiment uses a sterile 96-well plate, add 200μl of the above cell suspension to each well, and place it in a cell culture incubator for overnight culture. The next day, add different concentrations of the sample to be tested, and the concentration gradient is set to 80μg / ml, 40μg / ml, 20μg / ml, 10μg / ml, 5μg / ml, 0μg / ml, and 3 replicates for each concentration. The control group uses the same volume of sterile PBS, and then continues to culture in a constant temperature incubator at 37°C and 5% CO2 for 24 hours. Add 10μl of 5mg / ml MTT solution to each well, and continue to culture in an incubator under light-proof conditions for 4 hours. Finally, carefully aspirate and discard the liquid in the well, add 100μl of DMSO (dimethyl sulfoxide), place the 96-well plate on a shaker and shake slowly for 10 minutes until the crystals are dissolved, and use an enzyme marker to detect the light absorption value of each well at 490nm.
[0093] The test results are as attached Figure 2 As shown, the results indicate that the antibacterial polypeptide WRKB7 provided by the present invention has high cell proliferation ability and no cytotoxicity.
[0094] Experimental Example 4
[0095] Stability test
[0096] Use a sterile syringe to obtain 10mL of human blood and store it in an anticoagulant tube. Centrifuge at 4°C and 3500rpm for 30min, and carefully draw the yellow supernatant, which is the required plasma. Dilute the above plasma by half with sterile saline, and add the polypeptide WRKB7 to it, and control the final concentration of WRKB7 to 10mg / ml. Subsequently, the plasma containing the polypeptide WRKB7 was placed in a constant temperature incubator at 37°C for incubation, and 10μl was taken at 7 time points, including 0, 1, 2, 4, 6, 8, and 10 hours, respectively. The antibacterial activity of the polypeptide WRKB7 against Staphylococcus aureus after co-incubation with plasma was detected by the inhibition zone method, and two replicates were set for each time point.
[0097] The test results are as attached Figure 3 As shown, the antibacterial activity of WRKB7 was still detectable after incubation with serum for 10 h.
[0098] Experimental Example 5
[0099] Free radical scavenging activity of WRKB7 (DPPH radical scavenging assay)
[0100] DPPH (2,2-diphenyl-1-picrylhydrazyl hydrate) is a stable nitrogen-centered lipid free radical with three benzene rings in its structure. Its methanol or ethanol solution is purple and has strong absorption near 517nm. When there is an antioxidant with hydrogen-donating ability, the color changes from dark purple to light yellow, and the absorbance at 517nm decreases. The degree of decrease in its absorbance is positively correlated with its ability to scavenge free radicals, so it can be used to detect antioxidant activity. Weigh a certain amount of DPPH (Sigma, USA), dissolve it in methanol, and prepare 6×10 -5 M solution, freshly prepared and used. Mix 48μl DPPH solution and 2μl sample (2mg / ml) (the final mass ratio of sample to DPPH is 3:1), let stand at room temperature in the dark for 30 minutes, and measure the absorbance at 517nm. The blank control group uses the sample dissolution medium instead of the sample to be tested. The experiment was performed in triplicate, and methanol was used when zeroing the UV spectrophotometer. DPPH·scavenging rate (%) = (AB-AA) / AB×100 (AB: absorbance of blank; AA: absorbance of sample). When the sample concentration was 60μg / ml, the scavenging rate of WRKB7 for DPPH free radicals was 46.8±5.2%, indicating that WRKB7 has good free radical scavenging ability.
[0101] Experimental Example 6
[0102] Effect of WRKB7 on mast cell degranulation
[0103] Wistar rats were killed by cervical dislocation, and 10 ml of Tyrode's solution (137 mM NaCl, 2.7 mM KCl, 1.36 mM CaCl2, 0.49 mM MgCl2, 0.36 mM NaH2PO4, 11.9 mM NaH2CO3, and 5.04 mM D-glucose) was injected intraperitoneally. The abdomen was gently massaged for 10 min, and the peritoneal cavity was opened to aspirate the Tyrode's solution (containing mast cells). The cells were centrifuged at 1000 rpm for 5 min, washed with Tyrode's solution once, and then the mast cells were suspended with 1-2 ml of Tyrode's solution. 10 μl of the sample and 90 μl of the cell suspension were incubated at 37°C for 15 min, and then centrifuged at 3000 rpm for 5 min. 50 μl of supernatant was taken, and 50 μl of substrate (3 mg of ρ-nitrophenyl-N-acetyl-β-D-glucosaminidine dissolved in 10 ml of 200 mM, pH 4.5 sodium acetate buffer) was added. After incubation for 6 hours, 100 μl of Na2CO3 at pH 10.0 was added to terminate the reaction, and the absorbance was measured at a wavelength of 405 nm. The negative control was the sample dissolution medium, and the positive control was 0.1% (v / v) Triton X-100. This experiment was repeated 3 times. The mast cell degranulation rate was calculated according to the following formula: mast cell degranulation rate % = [(mast cell degranulation amount in the sample group - mast cell degranulation amount in the negative control group) / mast cell degranulation amount in the positive control group] × 100%. The results showed that the mast cell degranulation rate of WRKB7 was 43.7% at a concentration of 50 μg / ml. The strong activity of WRKB7 in promoting mast cell degranulation indicates that it can affect the immune response and play a role in the inflammatory response.
[0104] Experimental Example 7
[0105] Effects of WRKB7 on skin inflammation in rats
[0106] 40 SD rats were depilated with depilatory cream on the back one day before animal modeling, with an area of 3cm×3cm. One day after depilation, 50μL 5% 2,4-dinitrochlorobenzene (DNCB) was applied to the depilated area for the first sensitization experiment; 8 days later, the depilated area was depilated for the second time, and 100μL 1% DNCB was applied to the depilated area on the second day of the second depilation for the second sensitization. In the next 3 weeks, 100μL 1% DNCB was used for sensitization once a week for 4 consecutive weeks. Three days after the last sensitization, the modeling was completed, and the rat skin surface showed symptoms such as keratinization, flaky erythema, scab, elongation of epidermal protrusions, acanthosis, and mild spongioedema, which indicated that the modeling was successful. Thirty SD rats with successful modeling were randomly divided into a model group (normal saline), a positive control group (0.1% hydrocortisone butyrate cream, dose: 1.0g / kg) and an experimental group (dose: 80μg / ear) according to the digital random table method, with 10 rats in each group, and the drugs were administered percutaneously for 5 weeks. Before treatment, there was no significant difference in the scores of lichen, erythema, and papules among the three groups of rats (P>0.05); after treatment, the scores of lichen, erythema, and papules in the positive control group and the experimental group were significantly lower than those in the model group (P<0.05), as shown in Table 2.
[0107] Table 2 The therapeutic effect of WRKB7 on rat skin inflammation model
[0108]
[0109] Note: * P<0.05, significant difference compared with the model group after treatment; # P<0.05, significant difference compared with before treatment.
[0110] The above results show that the new polypeptide WRKB7 designed by the present invention can directly kill pathogens, promote mast cell degranulation and other pathways to regulate inflammatory factors and reduce inflammatory responses. It has significant functions and rich action pathways. WRKB7 has low hemolytic activity, no cytotoxicity, and high stability, and can be used in drugs or skin care products for the treatment of skin inflammation.
[0111] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention rather than all the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. An antimicrobial peptide WRKB7, characterized in that: The amino acid sequence of the antimicrobial peptide WRKB7 is shown in SEQ ID No.
1.
2. The method for preparing the antimicrobial peptide WRKB7 according to claim 1, characterized in that: The following steps are involved: The crude polypeptide was synthesized using solid phase synthesis method according to the amino acid sequence shown in SEQ ID No.
1.
3. The preparation method according to claim 2, characterized in that: After the crude polypeptide is synthesized, the crude polypeptide is purified; the purification includes high performance liquid chromatography purification.
4. The preparation method according to claim 3, characterized in that: The high performance liquid chromatography purification comprises: dissolving the crude polypeptide in a trifluoroacetic acid aqueous solution with a volume concentration of 0.1% to obtain a sample to be tested, loading the sample to be tested, using a binary mobile phase for gradient elution, and detecting at a wavelength of 215 nm at 25° C.; The binary mobile phase includes mobile phase A and mobile phase B; the mobile phase A is a trifluoroacetic acid aqueous solution with a volume concentration of 0.1%; the mobile phase B is a trifluoroacetic acid acetonitrile solution with a volume concentration of 0.1%; The gradient elution procedure is as follows: within 30 minutes, the content of mobile phase B in the eluent increases linearly from 0% to 80%; The eluent flow rate of the gradient elution is 1 mL / min; The chromatographic column for high performance liquid chromatography purification is a silica gel alkyl bonded phase C18 column.
5. The preparation method according to claim 3, characterized in that: After the crude polypeptide is purified, the method further includes determining the molecular weight and isoelectric point of the purified polypeptide.
6. The preparation method according to claim 5, characterized in that: Determining the molecular weight of the purified polypeptide comprises determining the molecular weight of the purified polypeptide using matrix-assisted laser desorption ionization time-of-flight mass spectrometry; The method of using matrix-assisted laser desorption ionization time-of-flight mass spectrometry to determine the molecular weight of the purified polypeptide comprises: dissolving the purified polypeptide in deionized water to obtain a purified polypeptide solution; Mixing the purified polypeptide solution and the saturated matrix solution to obtain a sample to be tested; Determine the molecular weight of the sample using matrix-assisted laser desorption ionization time-of-flight mass spectrometry; The concentration of the purified polypeptide in the purified polypeptide solution is 1 μmol / mL; The volume ratio of the purified polypeptide solution to the saturated matrix solution is 1:1; The preparation method of the saturated matrix solution comprises: Dissolving α-cyano-4-hydroxycinnamic acid in acetonitrile solution to prepare a saturated solution, centrifuging, and taking the supernatant to obtain a saturated matrix solution; The acetonitrile solution uses an acetonitrile aqueous solution with a volume concentration of 50% as a solvent and contains trifluoroacetic acid with a volume concentration of 0.1%.
7. Use of the antimicrobial peptide WRKB7 according to claim 1 or the antimicrobial peptide WRKB7 prepared by the preparation method according to any one of claims 2 to 6 in the preparation of antimicrobial and / or antioxidant products; The types of the antibacterial bacteria are Staphylococcus aureus and / or Escherichia coli.
8. Use of the antimicrobial peptide WRKB7 according to claim 1 or the antimicrobial peptide WRKB7 prepared by the preparation method according to any one of claims 2 to 6 in the preparation of a medicine for treating skin inflammation.
9. A cosmetic or medicine, characterized in that: Contains the antimicrobial peptide WRKB7 according to claim 1 or the antimicrobial peptide WRKB7 prepared by the preparation method according to any one of claims 2 to 6.
